Engineered immune cells take aim at two cancer targets in hard-to-treat bile duct cancers

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened after standard chemotherapy. Participants receive the NK cells along with a short course of chemotherapy to prepare the immune system. The study first checks safety and dosing, then looks at whether the therapy shrinks tumors and how long any benefit lasts.